Current Hypertension Reports

, Volume 7, Issue 4, pp 298–303

Antihypertensive treatment and new-onset diabetes mellitus

Authors

  • Tonje Amb Aksnes
    • Clinica Medica, Ospedale S GerardoUniversity of Milan-Bicocca
  • Henrik M. Reims
    • Clinica Medica, Ospedale S GerardoUniversity of Milan-Bicocca
  • Sverre E. Kjeldsen
    • Clinica Medica, Ospedale S GerardoUniversity of Milan-Bicocca
  • Giuseppe Mancia
    • Clinica Medica, Ospedale S GerardoUniversity of Milan-Bicocca
Article

DOI: 10.1007/s11906-005-0029-9

Cite this article as:
Aksnes, T.A., Reims, H.M., Kjeldsen, S.E. et al. Current Science Inc (2005) 7: 298. doi:10.1007/s11906-005-0029-9

Abstract

The various antihypertensive regimens have varying effects on glucose metabolism and the development of diabetes mellitus. Recent large hypertension trials have shown great differences in the development of new-onset diabetes among antihypertensive drug therapies. The incidence of diabetes is unchanged or increased by thiazide diuretics and β-adrenergic blockers, and unchanged or decreased by angiotensin-converting enzyme inhibitors, calcium channel blockers, and angiotensin-receptor blockers. The differences in new-onset diabetes mellitus have not influenced the outcome of cardiovascular mortality and morbidity in all of the large clinical trials, but drug-induced diabetes among hypertensive patients is known to carry the same cardiovascular risk as that seen in patients with previously known diabetes; however, it might take years for the increased risk to become apparent.

Copyright information

© Current Science Inc 2005